Simos Simeonidis - Jun 9, 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jun 9, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 04:16 PM
Previous filing
Jun 15, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +90K $0.00 90K Jun 9, 2022 Common Stock 90K $0.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.